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Sporadic late-onset nemaline myopathy
with MGUS
Long-term follow-up after melphalan and SCT
ABSTRACT
Objective: Sporadic late-onset nemaline myopathy (SLONM) is a rare, late-onset myopathy that pro-
gresses subacutely. If associated with a monoclonal gammopathy of unknown significance (MGUS),
the outcome is unfavorable: the majority of these patients die within 1 to 5 years of respiratory fail-
ure. This study aims to qualitatively assess the long-term treatment effect of high-dose melphalan
(HDM) followed by autologous stem cell transplantation (SCT) in a series of 8 patients with
SLONM-MGUS.
Methods: We performed a retrospective case series study (n 5 8) on the long-term (1–8 years)
treatment effect of HDM followed by autologous SCT (HDM-SCT) on survival, muscle strength,
and functional capacities.
Results: Seven patients showed a lasting moderate–good clinical response, 2 of them after the
second HDM-SCT. All of them had a complete, a very good partial, or a partial hematologic
response. One patient showed no clinical or hematologic response and died.
Conclusions: This case series shows the positive effect of HDM-SCT in this rare disorder. Factors
that may portend an unfavorable outcome are a long disease course before the hematologic treat-
ment and a poor hematologic response. Age at onset, level and type of M protein (k vs l), and
severity of muscle weakness were not associated with a specific outcome.
Classification of evidence: This study provides Class IV evidence that for patients with SLONM-
MGUS, HDM-SCT increases the probability of survival and functional improvement. Neurology®
2014;83:2133–2139
GLOSSARY
HDM 5 high-dose melphalan; MGUS 5 monoclonal gammopathy of unknown significance; SCT 5 stem cell transplantation;
SLONM 5 sporadic late-onset nemaline myopathy.
Sporadic late-onset nemaline myopathy (SLONM) is a rare, late-onset myopathy that progresses
subacutely. Limb-girdle and axial weakness and atrophy predominate the clinical picture. Distal
weakness, head drop, respiratory insufficiency, and dysphagia can also occur.1,2 Patients may be
suspected to have motor neuron disease because of the rapid course and severe atrophy. Rec-
ognition of nemaline rods on trichrome and a-actinin staining or electron microscopy is crucial.
SLONM is in a significant proportion of cases associated with a monoclonal gammopathy of
unknown significance (MGUS), a combination that portends an unfavorable outcome: the
majority of these patients die within 1 to 5 years of respiratory failure.3 In 2008, our 2 groups
concurrently but independently reported the effective treatment of 2 patients with SLONM
associated with MGUS (SLONM-MGUS) with high-dose melphalan (HDM) followed by
autologous stem cell transplantation (SCT). Both patients showed significant increase of muscle
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Table 1 Main features of the myopathy in 8 patients with SLONM and MGUS
Patient
1 2 3 4 5 6 7 8
Sex M M F F F F M F
Age at onset, y 38 59 47 63 60 39 54 36
Symptoms at onset Proximal upper . lower limb
weakness
Proximal upper and
lower limb weakness
Proximal lower limb
weakness
Proximal lower
limb weakness
Proximal lower limb
weakness
Upper and lower girdles
weakness, neck weakness
Proximal lower limb
weakness
Limb-girdle
weakness and pain
Age at diagnosis, y 40 61 49 64 66 44 55 38
Treatment before
diagnosis
Prednisone None Laminectomy None None Methotrexate,
prednisolone, IVIg, plasma
exchanges, rituximab
None Methylprednisolone,
plasma exchange
CK, U/L (normal
<414 U/L for
males; <217 for
females)
167 238 150 160 65 Normal 170 133
EMG Myopathic, fast recruitment Myopathic and
neurogenic
Myopathic Myopathic Myopathic Myopathic Myopathic Polyphasic MUPs in
proximal muscles
Muscle biopsy/
biopsies (site)
1st (VL): neurogenic
changes, secondary
myopathic changes;
revaluation 1st: nemaline
rods
1st (VL): neurogenic
changes, secondary
myopathic changes;
2nd (VL): nemaline rods
1st (VL): COX-deficient
fibers but no EM signs of
mitochondrial myopathy;
2nd (VL): nemaline rods
1st (D): type
1 fiber atrophy;
2nd (D): nemaline
rods
1st (VL): no inflammation
neither vacuoles; 2nd (VL):
atrophic and lobulated fibers;
3rd (VL): nemaline rods
1st and 2nd (D): atrophic
fibers; 3rd (BB): pseudo-
perifascicular atrophy; 4th
(VL): nemaline rods
Atrophic fibers and
nemaline rods (D)
1st (D): normal; 2nd
(VL): nemaline rods
EM Nemaline rods Nemaline rods Nemaline rods Nemaline rods ND Nemaline rods Nemaline rods Nemaline rods
Age at moment of
the SCT, y
40 61 50 66 71 44 56 39
Symptoms at the
moment of the SCT
Severe weakness affecting
proximal arms . legs, and
neck extensors (head drop);
winging of scapula
Severe weakness
affecting proximal arms
. legs, and winging of
scapula
Severe weakness affecting
proximal arms and legs, and
winging of scapula
Lower limbs
weakness [;
proximal upper
limbs 1 axial
weakness
Severe weakness affecting
proximal limbs, trunk flexors,
and neck extensors (head
drop)
Myalgia, severe weakness
affecting proximal limbs,
trunk flexors, and neck
extensors (head drop)
Severe weakness
affecting proximal
legs . arms and
neck extensors
Severe proximal
weakness, including
axial muscles with
head drop
Walking Walking independently Walking with a cane Walking with walker or with
partner
Some steps with
help; WCB for 2 y
Walking at home with walker WCB Waddling gait; later
WCB
WCB
Bulbar weakness Mild dysarthria and
dysphagia
Mild dysarthria and
dysphagia
Dysphagia No No No Mild Severe dysphagia
(PEG)
Facial weakness
(incomplete eye
closure or reduced
touting of lips)
Mild Mild Mild No No No Mild Mild
Respiratory
weakness
No No No No No Yes: VC Y 40% Mild Yes: VC Y 54%
Abbreviations: BB 5 biceps brachii muscle; CK 5 creatine kinase; COX 5 cyclooxygenase; D 5 deltoid muscle; EM 5 electron microscopy; IVIg 5 IV immunoglobulin; MGUS 5 monoclonal gammopathy of unknown
significance; MUP 5motor unit potential; ND 5 not determined/not documented; PEG 5 percutaneous endoscopic gastrostomy; SCT 5 stem cell transplantation; SLONM 5 sporadic late-onset nemaline myopathy;
VC 5 vital capacity; VL 5 vastus lateralis muscle; WCB 5 wheelchair bound.
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Table 2 Response to HDM with autologous SCT
Patient
1 2 3 4 5 6 7 8
After 1st
graft
After 2nd
graft
After 1st
graft
After 2nd
graft
Neurologic features
Age at onset, y 38 40 59 47 63 60 39 46 54 36
Duration before
SCT, y
2 2.5 2 2 11 5 2 3
Follow-up after
graft
4 y 3.5 y 4 y 2.5 y 8 y 5 y 2.5 y 4 mo 6 y 12 mo
Limb weakness UL:
0 to 111 before/
after graft
111/11 111/11 111/11 111/11 111/1 111/111 111/111 111/111 111/11 111/11
Limb weakness LL:
0 to 111 before/
after graft
11/1 11/1 11/1 11/1 111/1 111/111 111/111 111/11 111/11 111/11
Arm abduction
before/after graft, °
20/45 30/45 ND/70 (R) 60 (L) 40 (R) 30 (L)/60 45/150 40/30 30/2 y: 60; 2.5 y:
worsened
0/40 20/90 0/20
Walk assistance
before/after graft
Walking
unaided/
running
Walking
unaided/
running
Walking with cane/
walking with cane
(longer distance
and higher speed)
Walking with walker/
walking with cane
WCB for
outside,
walker at
home/walk
unaided
WCB outside, walker
at home/bedridden
WCB continuously/
from 3rd mo to 2 y:
walks 10 m, alone.
Thereafter worsening:
permanent WCB
WCB/WCB
(distal LL
recovery)
Walking with
walker/walk
unaided
WCB/WCB but
walking a few
meters with
walker
Walton CSS before/
after graft
1/2 1/2 6/4 6/4 7/2 6/10 7/from 3rd to 24th
mo 6; after 7
7/8 9/3 9/8
Brooke scale
before/after graft
4/2 3/2 4/2 ND/ND 4/2 ND/ND ND/ND ND/ND 5/2 5/4
Facial, bulbar,
respiratory
involvement before/
after graft
Yes, yes,
no/no, no,
no
ND/no, no, no Yes, yes, no/no, no,
no
Yes, yes, no/no, no, no No, no, no/
no, no, no
No, no, yes/no, no, no No, no, yes/no,
no, ND
No, no, ND,/no,
yes, yes
aspiration
pneumonia
No, no, yes/yes,
no, no
Yes/no
Head drop before/
after graft
Severe/mild Severe/mild No/no Yes/no Yes/no Yes/yes Yes/yes Yes/yes Mild/no Yes/no
Hematologic features
M protein IgG k IgG l IgG l IgG l IgG k IgG l IgG k IgG k
M protein level
before graft, g/L
7.4 0.1 Detectable but
unquantifiable
3.3 2.6 2.6 9.4 (20 mo before);
detectable but
unquantifiable
(3 mo before)
17.8 11 0.24
M protein level after
graft, g/L; last
examination
0; 3.0 at 3 y
9 mo
Detectable
but
unquantifiable
Detectable but
unquantifiable; 0
after lenalidomide
Detectable but
unquantifiable
0 5.8 0; 17.8 at 2 y 5.6 Detectable but
unquantifiable
at 6 mo, then
0 at 6 y
0
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Table 2 Continued
Patient
1 2 3 4 5 6 7 8
After 1st
graft
After 2nd
graft
After 1st
graft
After 2nd
graft
Bone marrow biopsy
before graft
10%–20%
monoclonal
plasma cells
1% monoclonal
plasma cells
,5% monoclonal plasma
cells;
immunophenotyping:
0.43% plasma cells, of
which 0.27% monoclonal
4%
monoclonal
plasma
cells
4.5 y before graft: 8%
monoclonal plasma
cells; 4 mo before, rich
bone, 0% plasma cells
4.5 y before graft:
hypoplasia, no abnormal
infiltration; 4 mo before
graft: 2% monoclonal
plasma cells
5%–10%
monoclonal plasma
cell
Normal
Therapies before
graft: PE, IVIg,
steroids,
cytostatics,
melphalan (just
before graft)
Prednisone,
melphalan
IVIg,
rituximab,
melphalan
Melphalan Melphalan Melphalan PE, dexamethasone,
cyclophosphamide,
Alkeran, melphalan
PE, IVIg, prednisolone,
methotrexate, rituximab,
melphalan
Melphalan Melphalan Methylprednisolone,
PE
Therapies after
graft
Lenalidomide
(10 mg daily
21/28 d)
Lenalidomide (10
mg lenalidomide
21/28);
dexamethasone
(40 mg weekly)
Lenalidomide (25 mg daily
21/28 d); dexamethasone
(20 mg weekly) up to 2.5
y after SCT
None Lenalidomide;
dexamethasone
(started 2 y after
SCT); dose ND
None None None None
Summary of
treatment response
M protein IgG k IgG l IgG l IgG l IgG k IgG l IgG k IgG k
M protein level
before graft, g/L
7.4 0.1 n.q. 3.3 2.6 2.6 9.4; n.q. (after
treatment)
17.8 11 0.24
Follow-up after
graft
4 y 3.5 y 4 y 2.5 y 8 y 5 y 2.5 y 8 mo 6 y 12 mo
Clinical response II I I I I IV II I I I
Hematologic
response
CR (3 y 9
mo); PD
after that
VGPR CR VGPR CR PD CR (2 y); PD after
that
PR CR CR
Abbreviations: CR5 complete response; CSS5 clinical severity score; HDM5 high-dose melphalan; IgG5 immunoglobulin G; IVIg5 IV immunoglobulin; LL5 lower limb; ND5 not determined/not documented; PD5
progressive disease; PE 5 plasma exchange; PR 5 partial response; SCT 5 stem cell transplantation; SD 5 stable disease; UL 5 upper limb; VGPR 5 very good partial response; WCB 5 wheelchair bound.
The hematologic response to the HDM with SCT and to other chemotherapy was classified according to international criteria (International Myeloma Working Group uniform response criteria)11: CR 5 no M protein
in serum and urine and #5% plasma cells in bone marrow; VGPR 5 M protein only detectable on electrophoresis or $90% reduction of M protein in serum; PR 5 $50% reduction of serum M protein and $90%
reduction of 24-hour urine M protein; SD 5 no response; PD 5 increase of .25% from lowest response value in any M protein level. Muscle strength was assessed with manual muscle testing (Medical Research
Council [MRC] scores 0–5), and muscle weakness was subsequently classified as 0 (MRC 5 in muscles of UL/LL);1 (MRC 4); 11 (MRC 3); or111 (MRC 0-1-2). To evaluate the effect of HDM and SCT on the disease
course, the overall clinical response was classified as: (I) lasting moderate–good response (increase of muscle strength of at least 2 muscle groups on manual muscle testing [MMT] and any functional improvement
during follow-up); (II) temporarily moderate–good (initial increase of muscle strength of at least 2 muscle groups on MMT and any functional improvement with secondary decrease of muscle strength of at least 2
muscle groups on MMT or functional loss during follow-up); (III) poor (no increase of muscle strength of at least 2 muscle groups on MMT or not any functional improvement but slowing of the pretreatment clinical
deterioration); and (IV) no response (no alteration of the pretreatment disease course).
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strength and functional improvement up to
independent walking and even running in
one.4,5 The editorial rightly commented that
the duration of follow-up (15–24 months) was
short, and suggested the possible effectiveness
of alternative, safer therapies, such as thalido-
mide or lenalidomide.6 Since then, only 4 other
SLONM-MGUS patients have been reported in
the literature, with similar treatment responses
on HDM-SCT in 2 of them.7–9
This retrospective case series aims to assess
the long-term treatment response of HDM
followed by autologous SCT (HDM-SCT)
in 8 patients with SLONM-MGUS.
METHODS Methods of clinical, hematologic, and histopatho-
logic data collection, definitions of clinical and hematologic treat-
ment response, and information on patient consents are listed in
appendix e-1 on the Neurology® Web site at Neurology.org.
RESULTS The clinical response to treatment varied
from long-lasting moderate to good for 7 patients
(I: patients 1 [second HDM-SCT], 2, 3, 4, 6 [second
HDM-SCT], 7, and 8), to temporarily moderate–
good in 2 patients who subsequently received a
second HDM-SCT (II: patients 1 and 6), and no
response (IV: patient 5). In parallel, the hematologic
responses diverged from complete response (patients
1 [first HDM-SCT], 2, 4, 6 [first HDM-SCT], 7,
and 8), very good partial response (patients 1 [second
HDM-SCT] and 3), partial response (patient 6 [second
HDM-SCT]), to progressive disease (patient 5). This
latter patient showed neither a clinical nor a hematologic
response and died. For patient 6, the period after the
second HDM-SCT was particularly difficult because of
a severe aspiration pneumonia, requiring intensive care
management including tracheostomy and gastrostomy,
but a significant improvement gradually started after
3 months. Patient 8 was in very poor shape with
significant weight loss and swallowing problems when
she entered the hospital for SCT. She developed bilateral
aspiration pneumonia and had to be intubated, requiring
the HDM-SCT to be postponed. Table 1 presents the
main features of the myopathy, and table 2 shows the
responses to treatment. The individual case histories of
the 8 patients are added as appendix e-2 (figure).
The only completely unresponsive patient (patient
5) differed from the other patients for the following
characteristics: a particularly long duration before
the autologous HDM-SCT (11 years) and no hema-
tologic response after HDM. In the 2 patients with
only a temporary response to treatment (patients
1 and 6), the delay before the graft was variable: 2
and 5 years, respectively. In the first patient, muscle
weakness recurred in parallel with a reappearance of
M protein, although at a much lower level than before
(0.1 g/L against 7.4 g/L before first graft), probably
related to higher awareness and regular measurements.
In patient 6, the clinical worsening 2 years after the
graft was also associated with a large increase of M pro-
tein (17.8 g/L against 9.4 g/L before first graft). Age at
onset of muscle weakness, severity of muscle weakness
before HDM-SCT, and the level and type of M
protein and results of bone marrow aspiration before
the graft did not correlate with the clinical response.
Lastly, 4 patients were treated after HDM-SCT
with lenalidomide to prevent a hematologic relapse
after HDM-SCT or to induce a (unsuccessful) hema-
tologic response in the patient with stable disease after
treatment. However, 2 other patients remained in
complete response after HDM-SCT without the use
of lenalidomide so the value of adding this drug cannot
be ascertained.
DISCUSSION This case series shows the long-term
follow-up of 8 patients with SLONM-MGUS after
treatment with HDM-SCT. Seven patients showed
a lasting moderate–good clinical response (2 of which
only after the second treatment), 6 with a very good
Figure Quadriceps biopsy in case 5
Quadriceps biopsy showing numerous rods in Gomori trichrome staining (A) and on electron microscopy (B).
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partial or complete hematologic response, and one with
a partial hematologic response. One patient showed no
clinical or hematologic response and died. Factors that
may portend an unfavorable clinical outcome are a
long disease course before HDM-SCT and a poor
hematologic response to treatment. Age at onset,
level and type of M protein, and severity of muscle
weakness before the graft were not associated with
outcome. This underlines the importance of early
recognition of this disorder by M protein screening
and (repeated) muscle biopsies in clinically suspected
cases. Timely diagnosis will also enable start of
treatment when the patient is still in a relatively
good clinical condition.
The limitations of this case series are that it is a ret-
rospective study, the number of patients is limited, and
treatment is not blinded. However, it is the first long-
term follow-up of a series of SLONM-MGUS patients
treated with HDM-SCT and undoubtedly shows the
positive treatment response with a follow-up of 9
months to 8 years in this otherwise fatal disease.
SLONM pathophysiologic mechanisms are un-
known, but several observations are suggestive of
an association between the (level of) the M protein
and the disorder4,5: appearance of rods later in the
course of the disease (which in this series is unlikely
to be due to sampling error); responsiveness to anti-
plasma cell chemotherapy; disappearance of nema-
line rods after treatment; increase of the M protein
level preceding clinical deterioration; and the absence
of a hematologic response to HDM-SCT paralleling
the lack of clinical improvement in patient 5. The dis-
ease may therefore be classified as an MGUS with a
toxic M protein similar to POEMS (polyneuropathy,
organomegaly, endocrinopathy/edema, M protein, skin
abnormalities) syndrome. Here, not the aggregation
and deposition of the monoclonal antibodies in affected
tissue but the antibody activity toward autogenous anti-
gens, possibly augmented by other humoral mediators,
is considered causative.10 This and other MGUS with a
toxic M protein–like disorder show a similar response
after HDM-SCT as observed in this SLONM-MGUS
series. This calls for further investigations in the exact
role of the M protein in SLONM-MGUS.
Based on this series and the experience in manage-
ment of other hematologic diseases with dangerous
B-cell clones, we suggest that HDM-SCT should be
the first-line therapy for SLONM-MGUS: first, the
natural course of SLONM-MGUS is fatal; second,
the goal of treatment should be to suppress the clone
as soon as possible to reduce the monoclonal protein
and its toxic effects; third, treatment is preferably
started when the patient is still in a relatively good
clinical condition. Furthermore, because the severity
of SLONM is likely to be correlated to the quantity
and/or quality of the toxic M protein after HDM-
SCT, consolidation and maintenance therapy may
be considered to achieve and maintain an optimal
hematologic response.
In short, this retrospective SLONM-MGUS case
series on the long-term follow-up shows that the
probability of survival, muscle strength, and func-
tional capacities improve after treatment with HDM-
SCT (class IV evidence). Factors associated with positive
benefit of HDM-SCT in SLONM-MGUS are shorter
duration between onset of symptoms and treatment
and a good hematologic response to treatment. This
again underscores the importance of early recognition
of this rare, acquired myopathy.
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